Roidipedia.Compound reference & reporting
06 AUG 2026
CompoundsResearch chemical 25D-NBOH
Research chemicalResearch chemicalPhenethylaminePsychedelic5-HT2A agonistN-benzyl (NBOH)

25D-NBOH

Also known as 2C-D-NBOH · NBOH-2C-D

25D-NBOH is the N-(2-hydroxybenzyl) derivative of 2C-D, part of the NBOH series of potent 5-HT2A agonist psychedelics. It is orally inactive, taken sublingually, and shares the narrow safety margin, vasoconstriction and seizure risk characteristic of N-benzyl phenethylamines.

01 Overview

25D-NBOH is a little-known NBOH compound derived from 2C-D. NBOH substances substitute a 2-hydroxybenzyl for the NBOMe 2-methoxybenzyl group and are marketed similarly on blotter.

There are no controlled human data; information is anecdotal. Despite occasional framing as gentler than NBOMe, 25D-NBOH retains the class's steep dose-response and cardiovascular/neurological toxicity.

02 Mechanism

Potent agonist at serotonin 5-HT2A receptors; the N-2-hydroxybenzyl group confers high 5-HT2A affinity on the 2C-D scaffold.

03 Dosing

TierDoseRouteNotes
Threshold300–700 µgSublingualEstimated; sparse data.
Common700–2000 µgSublingualAnecdotal only.

04 Effects

EffectMagnitudeEvidence
Psychedelic effectsVisuals and altered cognition consistent with the NBOH family.5-9 hAnecdotal
StimulationBody load and tension.moderateAnecdotal

05 Side effects

EffectSeverityFrequencyEvidenceCountermeasures
VasoconstrictionCold extremities and hypertension.SevereCommonAnecdotal
Seizures and serotonergic toxicityOverdose can cause agitation, seizures and hyperthermia.Life-threateningUncommonAnecdotal

07 References

The NBOH series: pharmacology and forensic toxicologyDrug Testing and Analysis, 2019
EMCDDA NBOH/NBOMe overviewEMCDDA

08 Discussion0 comments

?
Sign in to add a comment…
Create account
Discussion is moderated. No sourcing, vendor names or price talk — those comments are removed, and repeat posts are banned.
This page is reference information, not medical advice. Doses and protocols are documented as they appear in the clinical literature and in practice — describing them is not a recommendation to use them. Countermeasures listed here are not a substitute for a physician. Legal status varies by jurisdiction and changes.